| アブストラクト | BACKGROUND: Granulocyte and monocyte adsorption therapy has been explored as an adjunctive treatment for sepsis due to its potential to modulate excessive systemic inflammation. However, clinical evidence characterizing its real-world use for sepsis remains limited. This study aimed to conduct an exploratory comparative assessment of granulocyte and monocyte adsorption apheresis-direct hemoperfusion (G1-DHP) in patients with sepsis. METHODS: We conducted a retrospective comparative study using a prospective multicenter dataset of patients treated with G1-DHP (G-1 trial) and three independent sepsis datasets (Japan Septic Disseminated Intravascular Coagulation [JSEPTIC-DIC], Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis, and Trauma [FORECAST], and Japan Medical Data Center [JMDC]) as controls. Propensity score matching was performed using one-to-one nearest-neighbor matching. The primary outcome was 28-day mortality. Secondary outcomes included ventilator-free period, intensive care unit (ICU)-free period, and improvements in organ dysfunction scores. Ordinal logistic regression and linear regression were used based on outcome characteristics. RESULTS: After matching, the cohorts included 71, 72, and 68 patient pairs for comparisons with JSEPTIC-DIC, FORECAST, and JMDC, respectively. 28-day mortality was significantly lower in the G-1 trial across all matched datasets (G-1 trial vs. JSEPTIC-DIC: 5.6% vs. 23%; G-1 trial vs. FORECAST: 5.6% vs. 28%; G-1 trial vs. JMDC: 5.9% vs. 38%, all P < 0.01). The G-1 trial had a significantly longer ventilator-free period and a trend toward a longer ICU-free period. G1-DHP was also associated with greater observed improvement in Sequential Organ Failure Assessment (SOFA) score by day 7 in comparison to controls. Improvements in liver and coagulation SOFA subscores were particularly notable. CONCLUSIONS: In this multi-dataset analysis, patients treated with G1-DHP showed lower mortality and more favorable clinical outcomes in comparison to external controls. These exploratory findings provide preliminary insights into the potential role of G1-DHP as an immunomodulatory approach in sepsis and warrant further evaluation in prospective studies. |
|---|
| ジャーナル名 | Journal of intensive care |
|---|
| Pubmed追加日 | 2026/3/17 |
|---|
| 投稿者 | Hisamune, Ryo; Yamakawa, Kazuma; Nakamura, Tomoyuki; Doi, Kent; Takahashi, Gaku; Moriyama, Kazuhiro; Ishihara, Takuma; Nishida, Osamu |
|---|
| 組織名 | Department of Emergency and Critical Care Medicine, Osaka Medical and;Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka, 569-8686, Japan.;kazuma.yamakawa@ompu.ac.jp.;Department of Anesthesiology and Critical Care Medicine, Fujita Health University;School of Medicine, Toyoake, Aichi, Japan.;Department of Emergency and Critical Care Medicine, The University of Tokyo,;Tokyo, Japan.;Department of Critical Care and Emergency, Iwate Prefectural Advanced Critical;Care and Emergency Center, Iwate Medical University, Shiwa, Iwate, Japan.;Innovative and Clinical Research Promotion Center, Gifu University Hospital,;Gifu, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41840740/ |
|---|
